---
document_datetime: 2025-11-23 08:07:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lartruvo.html
document_name: lartruvo.html
version: success
processing_time: 0.3040556
conversion_datetime: 2025-12-24 20:35:46.297268
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lartruvo

[RSS](/en/individual-human-medicine.xml/65539)

##### Revoked

This medicine's authorisation has been revoked

olaratumab

Medicine

Human

Revoked

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lartruvo](#news-on)
- [Related content](#related-content-461)
- [More information on Lartruvo](#more-information-on-lartruvo-462)
- [More information on Lartruvo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Lartruvo has been revoked by the European Commission.

Lartruvo : EPAR - Summary for the public

English (EN) (528.34 KB - PDF)

**First published:** 23/11/2016

**Last updated:** 02/09/2019

[View](/en/documents/overview/lartruvo-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-467)

български (BG) (597.72 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/bg/documents/overview/lartruvo-epar-summary-public_bg.pdf)

español (ES) (527.76 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/es/documents/overview/lartruvo-epar-summary-public_es.pdf)

čeština (CS) (578.67 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/cs/documents/overview/lartruvo-epar-summary-public_cs.pdf)

dansk (DA) (526.59 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/da/documents/overview/lartruvo-epar-summary-public_da.pdf)

Deutsch (DE) (529.16 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/de/documents/overview/lartruvo-epar-summary-public_de.pdf)

eesti keel (ET) (525.89 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/et/documents/overview/lartruvo-epar-summary-public_et.pdf)

ελληνικά (EL) (601.38 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/el/documents/overview/lartruvo-epar-summary-public_el.pdf)

français (FR) (528.02 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/fr/documents/overview/lartruvo-epar-summary-public_fr.pdf)

hrvatski (HR) (537.96 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/hr/documents/overview/lartruvo-epar-summary-public_hr.pdf)

italiano (IT) (526.55 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/it/documents/overview/lartruvo-epar-summary-public_it.pdf)

latviešu valoda (LV) (577.96 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/lv/documents/overview/lartruvo-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (541.33 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/lt/documents/overview/lartruvo-epar-summary-public_lt.pdf)

magyar (HU) (572.3 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/hu/documents/overview/lartruvo-epar-summary-public_hu.pdf)

Malti (MT) (579.62 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/mt/documents/overview/lartruvo-epar-summary-public_mt.pdf)

Nederlands (NL) (527.11 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/nl/documents/overview/lartruvo-epar-summary-public_nl.pdf)

polski (PL) (579.33 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/pl/documents/overview/lartruvo-epar-summary-public_pl.pdf)

português (PT) (525.28 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/pt/documents/overview/lartruvo-epar-summary-public_pt.pdf)

română (RO) (539.42 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/ro/documents/overview/lartruvo-epar-summary-public_ro.pdf)

slovenščina (SL) (571.31 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/sl/documents/overview/lartruvo-epar-summary-public_sl.pdf)

Suomi (FI) (525.26 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/fi/documents/overview/lartruvo-epar-summary-public_fi.pdf)

svenska (SV) (523.37 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/sv/documents/overview/lartruvo-epar-summary-public_sv.pdf)

## Product information

Lartruvo : EPAR - Product Information

English (EN) (901.3 KB - PDF)

**First published:** 23/11/2016

**Last updated:** 02/09/2019

[View](/en/documents/product-information/lartruvo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-625)

български (BG) (1.93 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/bg/documents/product-information/lartruvo-epar-product-information_bg.pdf)

español (ES) (1010.5 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/es/documents/product-information/lartruvo-epar-product-information_es.pdf)

čeština (CS) (1.34 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/cs/documents/product-information/lartruvo-epar-product-information_cs.pdf)

dansk (DA) (947.43 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/da/documents/product-information/lartruvo-epar-product-information_da.pdf)

Deutsch (DE) (827.56 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/de/documents/product-information/lartruvo-epar-product-information_de.pdf)

eesti keel (ET) (841.25 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/et/documents/product-information/lartruvo-epar-product-information_et.pdf)

ελληνικά (EL) (1.76 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/el/documents/product-information/lartruvo-epar-product-information_el.pdf)

français (FR) (990.48 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/fr/documents/product-information/lartruvo-epar-product-information_fr.pdf)

hrvatski (HR) (1.01 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/hr/documents/product-information/lartruvo-epar-product-information_hr.pdf)

íslenska (IS) (1.2 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/is/documents/product-information/lartruvo-epar-product-information_is.pdf)

italiano (IT) (1.03 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/it/documents/product-information/lartruvo-epar-product-information_it.pdf)

latviešu valoda (LV) (1.45 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/lv/documents/product-information/lartruvo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.09 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/lt/documents/product-information/lartruvo-epar-product-information_lt.pdf)

magyar (HU) (1.45 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/hu/documents/product-information/lartruvo-epar-product-information_hu.pdf)

Malti (MT) (1.53 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/mt/documents/product-information/lartruvo-epar-product-information_mt.pdf)

Nederlands (NL) (959.37 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/nl/documents/product-information/lartruvo-epar-product-information_nl.pdf)

norsk (NO) (998 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/no/documents/product-information/lartruvo-epar-product-information_no.pdf)

polski (PL) (1.48 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/pl/documents/product-information/lartruvo-epar-product-information_pl.pdf)

português (PT) (812.93 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/pt/documents/product-information/lartruvo-epar-product-information_pt.pdf)

română (RO) (1.04 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/ro/documents/product-information/lartruvo-epar-product-information_ro.pdf)

slovenčina (SK) (1.44 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/sk/documents/product-information/lartruvo-epar-product-information_sk.pdf)

slovenščina (SL) (1.48 MB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/sl/documents/product-information/lartruvo-epar-product-information_sl.pdf)

Suomi (FI) (952.72 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/fi/documents/product-information/lartruvo-epar-product-information_fi.pdf)

svenska (SV) (889.51 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/sv/documents/product-information/lartruvo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010541/201704 11/01/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lartruvo : EPAR - All Authorised presentations

English (EN) (455.85 KB - PDF)

**First published:** 23/11/2016

**Last updated:** 02/09/2019

[View](/en/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-377)

български (BG) (519.57 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/bg/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_bg.pdf)

español (ES) (497.61 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/es/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (481.69 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/cs/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (460.13 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/da/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (456.41 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/de/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (457.97 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/et/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (493.93 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/el/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_el.pdf)

français (FR) (456.7 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/fr/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (468.76 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/hr/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.69 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/is/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (463.86 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/it/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (490.44 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/lv/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (471.65 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/lt/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (476.63 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/hu/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (484.37 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/mt/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (460.37 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/nl/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (460.84 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/no/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_no.pdf)

polski (PL) (486.05 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/pl/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_pl.pdf)

português (PT) (459.3 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/pt/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_pt.pdf)

română (RO) (472.1 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/ro/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (483.87 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/sk/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (506.47 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/sl/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (493.84 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/fi/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (455.73 KB - PDF)

**First published:**

23/11/2016

**Last updated:**

02/09/2019

[View](/sv/documents/all-authorised-presentations/lartruvo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lartruvo Active substance olaratumab International non-proprietary name (INN) or common name olaratumab Therapeutic area (MeSH) Sarcoma Anatomical therapeutic chemical (ATC) code L01XC27

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/004216

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Eli Lilly Nederland B.V.

Papendorpseweg 83

Opinion adopted 15/09/2016 Marketing authorisation issued 09/11/2016 Revocation of marketing authorisation 22/07/2019 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lartruvo Article 20 referral - CHMP assessment report

Reference Number: EMA/254126/2019

English (EN) (3.04 MB - PDF)

**First published:** 22/08/2019

[View](/en/documents/referral/lartruvo-article-20-referral-chmp-assessment-report_en.pdf)

Lartruvo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (511.88 KB - PDF)

**First published:** 05/05/2017

**Last updated:** 02/09/2019

[View](/en/documents/procedural-steps-after/lartruvo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Lartruvo-H-C-PSUSA-10541-201704 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

English (EN) (504.3 KB - PDF)

**First published:** 23/01/2018

**Last updated:** 02/09/2019

[View](/en/documents/scientific-conclusion/lartruvo-h-c-psusa-10541-201704-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Lartruvo : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/742133/2016

English (EN) (5.78 MB - PDF)

**First published:** 23/11/2016

**Last updated:** 23/11/2016

[View](/en/documents/assessment-report/lartruvo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lartruvo

Adopted

Reference Number: EMA/CHMP/589981/2016

English (EN) (536.99 KB - PDF)

**First published:** 16/09/2016

**Last updated:** 02/09/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lartruvo_en.pdf)

#### News on Lartruvo

[EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo](/en/news/ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo) 26/04/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019) 01/02/2019

[No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life](/en/news/no-new-patients-should-start-treatment-lartruvo-after-study-shows-cancer-medicine-does-not-prolong-life) 23/01/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2016-corrected) 21/09/2016

[New treatment for patients with soft tissue sarcoma](/en/news/new-treatment-patients-soft-tissue-sarcoma) 16/09/2016

#### Related content

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0042160000) (initial marketing authorisation)

#### More information on Lartruvo

This product was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-15-1447) on 12 February 2015. Lartruvo was withdrawn from the Community register of orphan medicinal products by the European Commission in July 2019 at the time of the withdrawal of the marketing authorisation.

#### More information on Lartruvo

- [EMEA-001760-PIP01-15-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001760-pip01-15-m03)
- [Lartruvo - referral](/en/medicines/human/referrals/lartruvo)

**This page was last updated on** 02/09/2019

## Share this page

[Back to top](#main-content)